KiranNaqviMD

PubMed

• 82 citations
  Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
  Kiran Naqvi, Elias Jabbour, Carlos E. Bueso-Ramos, Sherry Pierce, Gautam Borthakur
  Blood. 2011-10-27
• 109 citations
  Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model
  Kiran Naqvi, Guillermo Garcia-Manero, Sagar Sardesai, Jeong Hoon Oh, Carlos E. Vigil
  Journal of Clinical Oncology. 2011-06-01
• 27 citations
  Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes
  Naval Daver, Kiran Naqvi, Elias Jabbour, Tapan M. Kadia, Courtney D. DiNardo
  American Journal of Hematology. 2014-05-01

Abstracts/Posters

• Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes
  Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP). 
  2019 ASCO Annual Meeting - 6/1/2019
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all